The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease

Published:2022-03-30 Issue:12 Volume:28 Page:1915-1923
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Patil Seema A¹,Bhat Shubha²,Limdi Jimmy K³,Farraye Francis A⁴,Cross Raymond K¹^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland School of Medicine , 685 W. Baltimore Street, Suite 8-00, Baltimore, MD, 21201 , USA

2. Departments of Pharmacy and Gastroenterology, Digestive Disease and Surgery Institute, Cleveland Clinic , 9500 Euclid Ave, Cleveland, OH, 44195 , USA

3. Division of Gastroenterology-Section of IBD, The Northern Care Alliance Hospitals NHS Foundation Trust, Manchester Academic Health Sciences, University of Manchester , 2.41 Fairfield House, Manchester, BL9 7TD , UK

4. Division of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Mayo Clinic , 4500 San Pablo Road, Jacksonville, FL, 32224 , USA

Abstract

Lay Summary Biosimilar medications have the potential to significantly reduce the cost of treatment in patients with inflammatory bowel disease. Observational studies have shown similar efficacy and safety of biosimilars to biologic reference products. Shared decision-making is crucial to the successful implementation of these agents.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

https://academic.oup.com/ibdjournal/advance-article-pdf/doi/10.1093/ibd/izac048/43162614/izac048.pdf

Reference59 articles.

1. Biosimilar drugs: concerns and opportunities.;Genazzani;Biodrugs,2007

2. Defining the difference: what makes biologics unique.;Morrow;Biotechnol Healthc,2004

3. The protein science of biosimilars.;Kuhlmann;Nephrol Dial Transplant.,2006

4. Need for a risk-based control strategy for managing glycosylation profile for biosimilar products.;Rathore;Expert Opin Biol Ther.,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East;Therapeutic Advances in Gastroenterology;2024-01

2. Editorial commentary on the Indian Journal of Gastroenterology —September–October 2022;Indian Journal of Gastroenterology;2022-09-22